227 related articles for article (PubMed ID: 30880318)
1. Study of correlation of level of expression of Wnt signaling pathway inhibitors sclerostin and dickkopf-1 with disease activity and severity in rheumatoid arthritis patients.
Singh A; Gupta MK; Mishra SP
Drug Discov Ther; 2019; 13(1):22-27. PubMed ID: 30880318
[TBL] [Abstract][Full Text] [Related]
2. Serum Sclerostin Level Among Egyptian Rheumatoid Arthritis Patients: Relation to Disease Activity, Bone Mineral Density and Radiological Grading.
Mehaney DA; Eissa M; Anwar S; Fakhr El-Din S
Acta Reumatol Port; 2015; 40(3):268-74. PubMed ID: 26535777
[TBL] [Abstract][Full Text] [Related]
3. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.
de Rooy DP; Yeremenko NG; Wilson AG; Knevel R; Lindqvist E; Saxne T; Krabben A; Leijsma MK; Daha NA; Tsonaka S; Zhernakova A; Houwing-Duistermaat JJ; Huizinga TW; Toes RE; Baeten DL; Brouwer E; van der Helm-van Mil AH
Ann Rheum Dis; 2013 May; 72(5):769-75. PubMed ID: 23041840
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.
Sun W; Tian L; Jiang L; Zhang S; Zhou M; Zhu J; Xue J
Clin Rheumatol; 2019 Apr; 38(4):989-995. PubMed ID: 30443790
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS).
Ruaro B; Casabella A; Paolino S; Pizzorni C; Ghio M; Seriolo C; Molfetta L; Odetti P; Smith V; Cutolo M
Clin Rheumatol; 2018 Nov; 37(11):3057-3062. PubMed ID: 30291470
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
7. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
[TBL] [Abstract][Full Text] [Related]
8. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
9. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
[TBL] [Abstract][Full Text] [Related]
10. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.
Brabnikova-Maresova K; Jarosova K; Pavelka K; Stepan JJ
Arthritis Res Ther; 2014 Oct; 16(5):460. PubMed ID: 25280749
[TBL] [Abstract][Full Text] [Related]
11. [Expression of plasma Dickkopf-1 in patients with rheumatoid arthritis and its correlation with peripheral blood T cell subsets].
Cao D; Wang Y; Wang LQ; Sun XL; Huang F; Meng Y; Ren LL; Zhang XW
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Sep; 53(2):255-260. PubMed ID: 33879894
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.
Boman A; Kokkonen H; Ärlestig L; Berglin E; Rantapää-Dahlqvist S
Clin Rheumatol; 2017 May; 36(5):1005-1012. PubMed ID: 28190118
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators.
Fassio A; Adami G; Gatti D; Orsolini G; Giollo A; Idolazzi L; Benini C; Vantaggiato E; Rossini M; Viapiana O
Int Immunopharmacol; 2019 Feb; 67():487-489. PubMed ID: 30599401
[TBL] [Abstract][Full Text] [Related]
14. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters.
Sakellariou GT; Iliopoulos A; Konsta M; Kenanidis E; Potoupnis M; Tsiridis E; Gavana E; Sayegh FE
Joint Bone Spine; 2017 May; 84(3):309-315. PubMed ID: 27369645
[TBL] [Abstract][Full Text] [Related]
16. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
17. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
[TBL] [Abstract][Full Text] [Related]
18. Potential significance of changes in serum levels of IL-17, TNF-α and DKK-1 in the progression of the rheumatoid arthritis.
Wang Q; Liu Y; Wu J; Chen S; Hu T; Liu Y; Li X; Li X; Wu Y; Yu J; Zeng T; Luo Y; Hu X; Tan LM
Autoimmunity; 2023 Dec; 56(1):2276068. PubMed ID: 37909152
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethö Z; Váncsa A; Bodnár N; Csomor P; Hamar A; Bodoki L; Bhattoa HP; Juhász B; Nagy Z; Hodosi K; Karosi T; FitzGerald O; Szücs G; Szekanecz Z; Szamosi S; Szántó S
Clin Rheumatol; 2020 Jan; 39(1):167-175. PubMed ID: 31522318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
